ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Código da empresaADMA
Nome da EmpresaADMA Biologics Inc
Data de listagemOct 17, 2013
CEOMr. Adam S. Grossman
Número de funcionários677
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 17
Endereço465 State Route 17
CidadeRAMSEY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal07446
Telefone12014785552
Sitehttps://www.admabiologics.com/
Código da empresaADMA
Data de listagemOct 17, 2013
CEOMr. Adam S. Grossman
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados